COVID-19: What Do Rheumatologists Need to Know?

ABSTRACT:

Purpose of review

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) emerged in December 2019, rapidly reaching global pandemic proportions. Coronavirus disease 2019 (COVID-19) has presented unique challenges to the rheumatology community. It is known that many individuals with rheumatic disease are at increased risk of severe disease from other infections, sparking a similar fear for COVID-19. In addition, medications routinely used in rheumatology practice are being trialled as treatments, with the potential for drug shortages for rheumatology patients.

Recent findings

Underlying comorbidities and active disease are associated with worse COVID-19 outcomes in patients with rheumatic disease. Tocilizumab and hydroxychloroquine have not proven to be effectiv

SUBMITTER: Fitzgerald GE 

PROVIDER: S-EPMC7785126 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature